JP2011520785A5 - - Google Patents

Download PDF

Info

Publication number
JP2011520785A5
JP2011520785A5 JP2011504523A JP2011504523A JP2011520785A5 JP 2011520785 A5 JP2011520785 A5 JP 2011520785A5 JP 2011504523 A JP2011504523 A JP 2011504523A JP 2011504523 A JP2011504523 A JP 2011504523A JP 2011520785 A5 JP2011520785 A5 JP 2011520785A5
Authority
JP
Japan
Prior art keywords
independently
optionally
substituted
substituents
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011504523A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011520785A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2009/000966 external-priority patent/WO2009127822A2/en
Publication of JP2011520785A publication Critical patent/JP2011520785A/ja
Publication of JP2011520785A5 publication Critical patent/JP2011520785A5/ja
Withdrawn legal-status Critical Current

Links

JP2011504523A 2008-04-16 2009-04-16 薬剤としての使用のためのビスアリール化合物 Withdrawn JP2011520785A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7117608P 2008-04-16 2008-04-16
US61/071,176 2008-04-16
PCT/GB2009/000966 WO2009127822A2 (en) 2008-04-16 2009-04-16 Bis-aryl compounds for use as medicaments

Publications (2)

Publication Number Publication Date
JP2011520785A JP2011520785A (ja) 2011-07-21
JP2011520785A5 true JP2011520785A5 (enExample) 2012-06-07

Family

ID=40897329

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011504523A Withdrawn JP2011520785A (ja) 2008-04-16 2009-04-16 薬剤としての使用のためのビスアリール化合物

Country Status (6)

Country Link
US (1) US20110071197A1 (enExample)
EP (1) EP2274280A2 (enExample)
JP (1) JP2011520785A (enExample)
CN (1) CN102036952A (enExample)
CA (1) CA2721452A1 (enExample)
WO (1) WO2009127822A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8377992B2 (en) * 2007-10-22 2013-02-19 The Wistar Institute TRBD-binding effectors and methods for using the same to modulate telomerase activity
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
PT2300013T (pt) 2008-05-21 2017-10-31 Ariad Pharma Inc Derivados de fósforo como inibidores de cinases
HRP20150355T1 (hr) 2009-01-12 2015-06-19 Pfizer Limited Sulfonamidni derivati
AR080375A1 (es) 2010-03-05 2012-04-04 Sanofi Aventis Procedimiento para la preparacion de 2-(cicloheximetil)-n-{2-[(2s)-1-metilpirrolidin-2-il] etil}-1,2,3,4-tetrahidroisoquinolina- 7-sulfonamida
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
RU2569678C2 (ru) 2010-04-22 2015-11-27 Вертекс Фармасьютикалз Инкорпорейтед Способ получения циклоалкилкарбоксамидо-индольных соединений
US9145407B2 (en) 2010-07-09 2015-09-29 Pfizer Limited Sulfonamide compounds
EP2704572B1 (en) 2011-05-04 2015-12-30 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
AU2013204563B2 (en) 2012-05-05 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
CN103539695B (zh) * 2012-07-12 2015-09-09 南京圣和药业股份有限公司 一种新的取代二苯醚类组蛋白去乙酰化酶抑制剂
DK2915804T3 (da) * 2012-10-31 2019-06-03 Fujifilm Toyama Chemical Co Ltd Nyt aminderivat eller salt deraf som TNF-alpha-inhibitorer
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
CA2916653C (en) 2013-06-27 2017-07-18 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
PT3131582T (pt) 2014-04-15 2018-10-08 Vertex Pharma Composições farmacêuticas para o tratamento de doenças mediadas pelo regulador de condutância transmembranar da fibrose quística
PT3203840T (pt) * 2014-10-06 2020-10-27 Vertex Pharma Moduladores do regulador da condutância transmembranar da fibrose quística
US10738030B2 (en) 2016-03-31 2020-08-11 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
LT3519401T (lt) 2016-09-30 2021-11-25 Vertex Pharmaceuticals Incorporated Cistinės fibrozės transmembraninio laidumo reguliavimo moduliatorius, farmacinės kompozicijos, gydymo būdai ir moduliatoriaus gamybos būdas
MX2021013639A (es) 2016-12-09 2022-09-30 Vertex Pharma Forma cristalina del compuesto 1, un modulador del regulador de conductancia transmembrana de fibrosis quística, procesos para su preparación, composiciones farmacéuticas del compuesto 1, y su uso en el tratamiento de fibrosis quística.
CA3066084A1 (en) 2017-06-08 2018-12-13 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
AU2018304168B2 (en) 2017-07-17 2023-05-04 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CN111051280B (zh) 2017-08-02 2023-12-22 弗特克斯药品有限公司 制备吡咯烷化合物的方法
TWI719349B (zh) 2017-10-19 2021-02-21 美商維泰克斯製藥公司 Cftr調節劑之結晶形式及組合物
MA51039A (fr) 2017-12-08 2020-10-14 Vertex Pharma Procédés pour préparer des modulateurs du régulateur de la conductance transmembranaire de la mucoviscidose
JP2021512105A (ja) 2018-01-31 2021-05-13 デシフェラ・ファーマシューティカルズ,エルエルシー 消化管間質腫瘍の治療のための併用療法
JP7523351B2 (ja) 2018-01-31 2024-07-26 デシフェラ・ファーマシューティカルズ,エルエルシー 肥満細胞症の治療のための併用療法
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
US11905268B2 (en) * 2018-08-10 2024-02-20 University Of Central Florida Research Foundation, Inc. Anthranilic acid derivatives and their use in the treatment of human cancers
NZ784949A (en) 2019-08-12 2025-09-26 Deciphera Pharmaceuticals Llc Ripretinib for treating gastrointestinal stromal tumors
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
AU2020419197B2 (en) 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Amorphous kinase inhibitor formulations and methods of use thereof
NZ789199A (en) 2019-12-30 2025-07-25 Deciphera Pharmaceuticals Llc Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
US20230255906A1 (en) * 2020-07-02 2023-08-17 The Brigham And Women`S Hospital, Inc. Targeting Serpin B9 in Cancer
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
KR102769394B1 (ko) * 2022-01-20 2025-02-17 동아대학교 산학협력단 아베난쓰라마이드 c의 합성 방법
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5334598A (en) * 1993-03-19 1994-08-02 Merck & Co., Inc. Six-membered ring fused imidazoles substituted with phenoxyphenylacetic acid derivatives
US5565485A (en) * 1993-03-19 1996-10-15 Merck & Co., Inc. Biphenyl compounds useful or endothelin antagonists
US5391566A (en) * 1993-07-20 1995-02-21 Merck & Co., Inc. Benzimidazolinones substituted with phenoxyphenylacetic acid derivatives
BRPI0512273A (pt) * 2004-06-18 2008-02-19 Millennium Pharm Inc inibidores do fator xa
EP1786421A2 (en) * 2004-07-09 2007-05-23 Cengent Therapeutics, Inc. Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases
KR20080077620A (ko) * 2005-12-05 2008-08-25 뉴로서치 에이/에스 벤즈이미다졸 및 gabaa 수용체 복합체를 조절하기위한 이의 용도
TW200825054A (en) * 2006-10-18 2008-06-16 Wyeth Corp Quinoline compounds
US20090069373A1 (en) * 2007-02-28 2009-03-12 Wyeth Quinoline Acids
TW200900072A (en) * 2007-03-22 2009-01-01 Arete Therapeutics Inc Soluble epoxide hydrolase inhibitors
MX2010001784A (es) * 2007-08-13 2010-03-15 Metabasis Therapeutics Inc Activadores novedosos de la glucocinasa.
CA2710452A1 (en) * 2007-12-21 2009-07-09 Wyeth Llc Imidazo [1,2-a] pyridine compounds

Similar Documents

Publication Publication Date Title
JP2011520785A5 (enExample)
JP2011520854A5 (enExample)
JP2010538052A5 (enExample)
JP2013040159A5 (ja) 有機金属錯体
JP2012087114A5 (ja) カルバゾール誘導体
RU2011116129A (ru) 1н-бензимидазол-5-карбоксамиды в качестве противовоспалительных средств
JP2011513410A5 (enExample)
JP2009535462A5 (enExample)
JP2012531433A5 (enExample)
JP2014526533A5 (enExample)
JP2006503068A5 (enExample)
JP2011121940A5 (ja) 発光素子
JP2010511721A5 (enExample)
JP2008510770A5 (enExample)
JP2009535358A5 (enExample)
JP2010504908A5 (enExample)
JP2012054542A5 (ja) トリアゾール誘導体および複素環化合物
JP2011520775A5 (enExample)
WO2010089510A3 (fr) Dérivés d'azaspiranyl-alkylcarbamates d'hétérocycles à 5 chaînons, leur préparation et leur application en thérapeutique
JP2013541600A5 (enExample)
JP2014509612A5 (enExample)
JP2006508979A5 (enExample)
JP2010254679A5 (ja) トリアゾール誘導体、発光素子、及び発光装置
JP2011506566A5 (enExample)
JP2013502441A5 (enExample)